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Abstract
Background: Attention Deficit/Hyperactive Disorder (ADHD) is often treated with medications but many parents
seek alternative treatment for fear of adverse effects. Increased oxidative stress has been observed in children and
adults with ADHD. We postulate that tocotrienol-rich fractions (TRF), a potent antioxidant from the natural Vitamin E
family, may help children with ADHD. The objective of this study is to determine if supplementation of TRF has an
effect on the symptoms of school-going children with ADHD.
Methods: Children aged between 6 to 12 years with ADHD were randomized to TRF 200 mg or placebo daily for 6
months. We measured the NICHQ Vanderbilt ADHD Parent (VAPRS) & Teacher (VATRS) Rating Scales at baseline, 3
months and 6 months. Plasma tocotrienol levels were also measured at each of the corresponding time. We used
ANOVA repeated measure and Spearman Rho’s for analysis.
Results: One hundred forty-six children were randomized. The VAPRS showed significant improvement after 3
months and 6 months in both groups (n = 73 each). The VATRS revealed greater improvement in the TRF group
but was not statistically significant (p = 0.07). The TRF group had higher levels of tocotrienols compared with the
placebo group at 3 and 6 months. There was a small but significant correlation of the alpha and gamma
tocotrienol levels with the change in VAPRS after 6 months.
Conclusion: TRF was not more effective than placebo in reducing the ADHD symptoms as measured by the VAPRS
and VATRS. Possible reasons for this include placebo-effects and supplementations given too late in life. Future
studies should consider using an objective outcome measurement (e.g. measuring attention-span) as well as earlier
age of supplementation.
Trial registration: ClinicalTrials.gov NCT01855984, date of registration 10 May 2013.
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Background
Attention Deficit/Hyperactive Disorder (ADHD) is the
commonest behavioural problem affecting school-going
children [1]. It is estimated that 5–12 % of school aged
children have ADHD [2] and accounts for up to 50 % of
referrals to Paediatric Psychiatric services [3]. Current
guidelines recommend the use of medication and behav-
ioural therapy for school-aged children with ADHD [1].
Medications are effective, but not without problems. Ad-
verse effects of medication, such as gastrointestinal and
sleeps disturbances from methylphenidate, are common
[4]. In the recently published Cochrane Systematic Review
on methylphenidate in children with ADHD, there was a
60 % increase in the risk of sleep problems and 266 % in-
crease in risk of reduced appetite among children taking
methylphenidate compared to placebo [5]. In addition,
many parents do not wish to ‘medicate’ their child because
they perceive that ADHD is not a ‘disease’ [6]. behavioural* Correspondence: mltan@pmc.edu.my
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source intensive [7]. Therefore it is not surprising many
parents seek alternative treatment such as nutritional sup-
plements, elimination diet, herbal treatment, acupuncture
and others for their ADHD children [8].
One such nutritional supplement is tocotrienols.
Tocotrienols is part of the Natural Vitamin E family. It
consists of 4 components—alpha, beta, delta and gamma
tocotrienols; also collectively known as tocotrienol-rich
fractions (TRF) [9]. It is found in abundance in palm oil
and rice bran oil [9]. TRF are potent anti-oxidants espe-
cially in the central nervous system [10]. Oxidative stress
has been found to be a potential cause of for neuronal
damage in several neurodevelopment conditions includ-
ing ADHD [11]. A meta-analysis of 6 studies found that
there is a modest increase in oxidative stress in ADHD
children and adults [12]. In addition, several studies had
found that with anti-oxidant usage, children with ADHD
had better behaviour scores [13–15]. TRF may also work
by inhibiting glutamate-induced activation of phospho-
lipase A2 (PLA2) in brain tissue, resulting in better me-
tabolism of polyunsaturated fatty acids (PUFAs) [16].
Abnormal metabolism of PUFAs has been implicated as
another cause of ADHD [17].
We conducted a randomized controlled trial to deter-
mine if supplementation of TRF compared to placebo
had an effect on the symptoms of school going children
with ADHD. We also looked at the safety of TRF in
these children as well as the correlation between toco-
trienol levels and their symptom scores.Methods
We conducted a randomized placebo-controlled trial in
the Child & Adolescent Psychiatric Clinic at two hospi-
tals in Penang, Malaysia.Eligibility and enrolment
Patient records were screened from February till October
2012. All patients born between 31.12.2000 and 1.1.2006
with the diagnosis of ADHD were invited to participate ei-
ther directly at the clinic or via a telephone call. The diag-
nosis of ADHD was made in accordance to the Diagnostic
and Statistical Manual of Mental Disorder- IV (DSM-IV)
criteria by physicians working in these hospitals using diag-
nostic interviews [18]. If the patient was on ADHD medica-
tion (e.g. methylphenidate or atomoxetine), the dose of the
medication had to remain unchanged for at least 3 months
before enrolment. Patients with syndromes, inborn errors
of metabolism, structural brain lesions, co-existing chronic
liver disease and those on concurrent anticoagulants or an-
tiplatelet drugs were excluded. Children who were unable
to swallow the capsule were also excluded.Randomization and allocation concealment
Computer-generated sequence generation and randomization
were performed by an independent person not in-
volved in the trial. Permutated block randomization of
unknown size to investigators was used. Allocation
concealment was by sequentially numbered sealed
opaque envelopes.
Intervention and placebo
Children were randomized to receive 200 mg of TRF or
placebo daily. These were given as 2 softgel capsules
daily containing either 100 mg TRF per capsule or pla-
cebo (soya bean based cooking oil).
Each 100 mg capsule of TRF (Tocovid Suprabio) con-
tained the following: alpha tocotrienol 30.76 mg, gamma
tocotrienol 56.40 mg, delta tocotrienol 12.84 mg, alpha
tocopherol 45.80 IU, plant squalene 25.64 mg, phytos-
terol complex 10.24 mg, phyto-carotenoid complex
180.00 mcg.
Blinding of the study personnel, participants and out-
come assessors were achieved by identical packaging of
both TRF and placebo manufactured by Hovid Bhd.
They were similar in size, shape, colour, texture and
outer-taste. At the end of the study, the effectiveness of
blinding was assessed by asking parents if they could
guess what their child received.
The investigators purchased both the TRF and placebo
capsules from the manufacturer.
Conduct of study
All of the children underwent a 1 month run-in with
placebo. The children were allowed to continue with
their existing ADHD medication. However, those who
were taking any over-the-counter nutritional supple-
ments were instructed to discontinue these at the point
of entry to the study and throughout the study. They
were not informed of the run-in period with placebo.
After the run-in period, children were randomized to
receive either placebo or TRF. The capsules were dis-
pensed as monthly supplies and they had to return the
previous month’s bottle. Adherence was assessed by per-
forming pill counts.
At the point of randomization (month 0), the accom-
panying parent or guardian would complete the NICHQ
Vanderbilt ADHD Parent Rating Scale (VAPRS). The
NICHQ Vanderbilt ADHD Teacher Rating Scale (VATRS)
was given to the children to be handed over to their class
teacher. The teachers’ scores were collected back using an
enclosed addressed and stamped envelope.
The children were then seen at 3 months and 6
months with a repeat VAPRS and VATRS scoring. Their
medical records were checked for alterations made to
their medications. All adverse events reported during
these visits were recorded. The children also had their
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after 3 and 6 months of the study. (See Fig. 1)
Ethics
This study was approved by the National Medical
Research Ethics Committee, Ministry of Health Malaysia
(NMRR No. 6767). Written consent was obtained from
the parent or guardian. Each child was told the nature of
his or her participation. This study was also registered
with ClinicalTrials.gov (NCT01855984).
Outcome measures
The primary outcome is the mean ADHD symptom
score as measured using the NICHQ Vanderbilt ADHD
Parent and Teacher Rating Scales (VAPRS & VATRS).
The secondary outcomes were adverse events, reported
changes in existing medication and correlation of
plasma tocotrienol levels with the ADHD symptom
score.
NICHQ Vanderbilt ADHD Parent and Teacher Rating Scale
(VAPRS & VATRS)
The VAPRS and VATRS were taken from the American
Academy of Paediatric ADHD Toolkit 1st Edition 2002
[19]. The psychometric properties of the VAPRS and
VATRS have been evaluated and found to be reliable
and valid to be used in practice and research [20, 21].
Both these scales were translated into the local language
and the translation had been previously tested in a test
population showing good internal reliability [22].Z
Fig. 1 Study Flow ChartThese scales are made up of two main components—the
‘Inattention’ and ‘Hyperactivity/Impulsivity’ scores. The
sum of these is known as the ‘Total Symptom Score’. The
maximum score for the Total Symptom Score is 54 (max-
imum 27 points for each of the two components). Higher
scores signify more problematic behaviour.
Tocotrienol levels
Tocotrienol levels were taken for all children and col-
lected in EDTA bottles. Each sample was centrifuged
immediately and the plasma frozen at −20 °C. All sam-
ples were transported in frozen state for laboratory
analysis not more than 3 months from the date of col-
lection. The plasma concentrations of alpha, gamma
and delta-tocotrienols were measured using a validated
high-performance liquid chromatographic (HPLC)
method with fluorescence detection [23].
Sample size calculation
There had been no previous studies using TRF for
ADHD. Sample size was calculated based on the study
“Effect of Supplementation with Polyunsaturated Fatty
Acids and micronutrients on learning and behaviour
problems associated with child ADHD” using the Total
DSM-IV scores from the Conner’s Parent Rating Scale
[24]. The scale is very similar to the VAPRS. By using
the Power and Sample Size Program for T test Version
2.1 with 80 % power and 5 % level of significance, the
sample size required was 63 participants for the treat-
ment group and 22 for placebo group [25]. However,
we aimed to recruit 80 children in each group in order
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out rate.
Statistical analysis
All analysis was done based on intention-to-treat (ITT)
principle. We used ANOVA repeated measure analysis
to compare the mean VAPRS and VAPRS at baseline, 3
months and 6 months. Missing data was handled by in-
terpolating values (for VAPRS) and iterative Markov
chain Monte Carlo (MCMC) method (for VATRS).Fig. 2 CONSORT FlowchartCategorical data were analysed using Chi square test.
Correlation between tocotrienol levels and VAPRS
Total Symptom Scores were done using Spearman
Rho’s. Statistical analyses were done using SPSS Version
22 [26] and Stata Version 12 [27].
Results
Between February and October 2012, a total of 158 chil-
dren (134 boys) were enrolled into the study. The mean
age of the children was 9.3 years (SD 1.8, minimum 5.4
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to randomization after the initial run in with placebo,
leaving 146 who were randomized. After randomization,
9 did not complete the study: 5 dropped out of the study
without reasons, 1 self-withdrew and 3 others were
stopped because of adverse events, not related to the
intervention (see Fig. 2).
The baseline characteristics of the two groups of chil-
dren who were randomized were similar (Table 1). The
teachers’ response rate throughout the study was very
poor. At baseline, only 95 (65 %) children had their
teacher’s score returned.Primary outcome 1: effect on the parent score (VAPRS) at
3 months and 6 months
The VAPRS Total Symptom Score showed significant re-
duction over time from baseline to 3 months for both
groups (p = <0.001). There was a further reduction from 3
months to 6 months for the placebo group but not
the TRF group. However, there was no statisticallyTable 1 Baseline characteristics of all the children in the study
Placebo
n = 73
TRF n = 73 p value
Age in years (mean, SD) 9.4 (1.7) 9.4 (1.9) 0.854






Mainstream 58 56 0.689
Special education 13 15
Others 2 2
Parental Education (n)









Medication for ADHD (n) 35 43 0.184
Mean Baseline VAPRS total
symptom score (SD)
28.97 (9.37) 28.91 (10.37) 0.976
Mean Baseline VATRS total
symptom score (SD)a
25.83 (10.35)a 25.40 (10.55)a 0.844
Baseline tocotrienol levels
(Median)
Delta (ng/ml) 9.900 10.050 0.967
Gamma (ng/ml) 43.30 48.40 0.709
Alpha (ng/ml) 24.60 26.40 0.935
aOnly 95 VATRS were returned (53 from placebo group, 42 from TRF group)significant difference between the groups at either
time point (p = 0.716) (see Table 2 and Fig. 3).
When we adjusted the VAPRS Total Symptom Scores
to age, gender, parent education or compliance to study
intervention, we found a significant effect of age on the
mean scores over time (p = 0.02) but there was no differ-
ence between the groups (p = 0.744). Children older than
9 years had the largest change. None of the other factors
contributed to the VAPRS Total Symptom Score.Primary outcome 2: effect on the teacher score (VATRS)
at 3 months and 6 months
Between 35 and 52 % of teacher-reported scores collected
at 3 different time points during the trial were missing.
The number of missing VATRS was equal between the
groups. Only 19 and 20 children in the placebo and TRF
group respectively had all 3 VATRS returned. Because the
VATRS were missing at random, we performed imput-
ation using Markov chain Monte Carlo (MCMC) method.
The following results are based on imputed data.
The VATRS Total Symptom Score showed significant
reduction over time from baseline to 3 months for both
groups (p = <0.001). The TRF group had a slightly
greater reduction in the score over time compared to
the placebo group but this was not statistically signifi-
cant (p = 0.07) (see Table 3 and Fig. 3).Secondary outcomes
Both groups had no statistically significant difference in
the number of children requiring a change in their ADHD
medications: three children in the placebo group and six
in the TRF group needed increased medications (p = 0.3).
One child in the placebo group and two children in the
TRF group had their medications decreased (p = 0.6).
The children in the placebo group had slightly more
adverse events reported during the study compared to
TRF group. However, this was not statistically significant
(p = 0.5) (See Table 4). All adverse events reported were
trivial and unlikely to be related to the study interven-
tion. The unwanted behaviour reported were mostly
temper tantrums which are common in ADHD.Tocotrienol levels
Tocotrienol levels were sampled at baseline, 3 months
and 6 months after intervention for all children. At base-
line, the levels were similar in both groups but at 3
months and 6 months, the TRF group had statistically
significant higher levels of delta, gamma and alpha toco-
trienols compared to placebo (Fig. 4). However, due to
the timing of blood sampling and relatively short half-
life of tocotrienols, most of the children did not have
levels as high as reported in literature [28].
Table 2 Mean VAPRS scores at baseline, 3 months and 6 months
VAPRS (Parent) Mean score p value
(time)
p value














Total symptoms score 28.97 9.37 28.91 10.37 24.36 9.12 24.63 9.04 23.16 8.43 24.41 9.78 <0.001 0.716
Inattention score 15.01 4.85 14.75 4.87 12.66 4.54 12.59 4.66 11.88 4.14 12.57 4.94 <0.001 0.858
Hyperactivity/Impulsivity score 13.95 5.74 14.30 6.15 11.71 5.36 12.04 5.22 11.06 4.89 11.83 5.80 <0.001 0.541
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the delta, gamma and alpha tocotrienol levels at 6
months correlated with the change in VAPRS at 6
months. A small but statistically significant correlation
was seen between alpha and gamma tocotrienol levels
with the change in the VAPRS Total Symptom Score
and Inattention Score at 6 months (Table 5).Adherence to treatment
Generally children in the TRF group only took 76 % of
the capsules dispensed compared to 86 % in the placebo
group and this was much lower in the last 3 months of
the study compared to the beginning. This could be be-
cause TRF have an unpleasant taste and some of the par-
ticipants bite into the capsule before swallowing them.Discussion
This study did not show any difference in the effect of
TRF supplementation over placebo on the symptoms of
ADHD as measured on the VAPRS and VATRS. To our
knowledge this is the first study investigating the effects
of TRF in children with ADHD. It is interesting to find
that regardless of which group the children were ran-
domized to, all parents reported improvement in theirFig. 3 Mean VAPRS and VARTS Total Symptom Score at baseline, 3 monthschildren’s behaviour after 3 and 6 months of interven-
tion especially in the first 3 months.
The dose of TRF and duration of supplementation is
sufficient and comparable to other studies using the
same preparation for a variety of conditions [29, 30].
Therefore, the lack of effectiveness over placebo is not
due to these factors.
There are several possibilities for the lack of differ-
ences between the two groups. The improvement
could have been due to ‘placebo effects’. It has been
suggested that if we give patients enough attention
with a pill to take for their condition, ask them to fill
out a questionnaire about their condition and see
them in regular intervals, majority would show im-
provement [31]. We had more frequent contact with
parents compared to their regular treatment while
participating in this study, as is also seen in other
studies [32]. This could in itself be therapeutic, lead-
ing to a difference in how the parents view their
children’s behaviour and subsequently result in an im-
provement in the children’s behaviour. We have
attempted to reduce bias by making sure that our al-
location and blinding was adequately done. We are
certain that there was no way any parent could guess
based on the feedback on blinding done at the end ofand 6 months
Table 3 Mean VATRS scores at baseline, 3 months and 6 months
VATRS (Teacher) Mean score p value (time) p value














Total symptoms score 25.76 10.34 25.26 10.54 25.27 10.27 22.13 10.20 22.59 10.08 20.75 10.03 <0.001 0.075
Inattention score 13.86 5.51 13.65 5.35 13.98 5.42 12.33 5.67 12.21 5.00 11.48 5.46 <0.001 0.116
Hyperactivity/
Impulsivity score
11.90 6.58 11.61 6.17 11.29 6.86 9.8 5.48 10.38 6.78 9.27 5.78 <0.001 0.131
Footnote: Analysis based on imputed data
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thought their children were receiving TRF and only a
minority (2–3 %) within each group thought they had
received placebo.
Another reason for this apparent lack of effectiveness
over placebo was the choice of outcome measure used.
The VAPRS was designed to capture the core symp-
toms of ADHD comprising of inattention, hyperactivity
and impulsiveness. It is also a self-administered score
and parent’s knowledge and perception about their
child’s behaviour could influence how they report the
score [33]. We found that the parents of our partici-
pants had difficulty quantifying their children’s behav-
iour to the scale within the VAPRS. They were more
able to describe the changes in behaviour verbally or
with a free text questionnaire. We firmly believe that
there could be other aspects of improvement in the
child because when we reviewed our end-of-study
questionnaire, we found some objective responses from
parents of children in the TRF group. Most of these re-
late to academic improvement and increase in duration
of concentration. It is possible that TRF had no effect
on the core symptoms of ADHD, but on other aspects
not captured in our outcome measure.
It was difficult to interpret the VATRS because
many of the teachers did not return the scales.
Teachers’ responses are likely to be more objective
compared to parents’ scores. However, they may not
be as observant as parents especially when they have
a large number of children in the class. SimilarTable 4 Adverse events reported
Placebo TRF
Gastrointestinal Disturbances 3 1
Fatigue 1 0
Unwanted behaviour Changes 5 5
Epistaxis 1 0
Rash 2 0
Others (Infections, curly hair, chest pain,
pimples, dry lips, fractured metatarsal
due to road accident, headache)
12 8
Total 24 14 p value = 0.57problems with teachers had been reported in another
study [24]. We found that the teachers reported bet-
ter scores in the TRF group compared with the pla-
cebo group after 6 months but the difference between
the groups did not reach statistical significance. How-
ever, it must be noted that this finding was seen in
the analysis with imputed data. If we could have
complete data, we might be able to be more certain
about this finding.
Although there was statistically significant correl-
ation between increase in alpha and gamma tocotrie-
nol levels with a greater change in score, the
correlation was very small. Again, this can be attrib-
uted to the fact that all reported improvement regard-
less of the group allocation.
Finally, it would be incomplete if we did not consider
the possibility that the intervention may have been too
late. There is evidence that dysregulated plasticity in the
developing brain is related to ADHD [34]. Newer studies
on nutrition are shifting to supplementing population at
risk to see if it will help prevent the condition. One such
study is the one using alpha tocopherols in extremely
low birthweight babies and the findings suggest that it
does change their behaviour outcomes [35].
Last but not least, TRF use is generally safe in chil-
dren. We did not encounter any major adverse events
and most of what was reported were unlikely related to
the intervention.Conclusion
This study was unable to demonstrate that TRF was bet-
ter than placebo in reducing ADHD symptoms as re-
ported by parent's and teacher’s scores. However, there
is a possibility that academic performances of these chil-
dren could be improved by the use of TRF.
In order to fully investigate the role of TRF in treat-
ment of children with ADHD, further studies should be
conducted using an objective outcome measurement
(especially measuring attention-span) in addition to the
parent's or teacher's reports as well as investigating the
effect of TRF in the ‘at risk’ population in early life even
before they developed any symptoms.
Table 5 Correlation between tocotrienol levels with change from baseline in VAPRS after 6 months
Change in VAPRS Total
Symptom Score after 6 months
Change in VAPRS Inattention
Score after 6 months
Change in VAPRS Hyperactive/Impulsivity
Score after 6 months
Correlation Coefficient p value Correlation Coefficient p value Correlation Coefficient p value
Delta-tocotrienol 0.106 0.2 0.133 0.1 0.051 0.5
Gamma- tocotrienol 0.193 0.02 0.202 0.01 0.148 0.07
Alpha- tocotrienol 0.184 0.03 0.167 0.05 0.139 0.09
Fig. 4 a, b, c Serum delta, gamma and alpha-tocotrienol levels according to groups at baseline, 3 months and 6 months for participants with
complete dataset (placebo group: n = 68, TRF group: n = 65)
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